5-[4-(2,5,7,8-tetramethyl-6-nicotinoyloxychroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione | 97323-02-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚酯
• 英文名称: 5-[4-(2,5,7,8-tetramethyl-6-nicotinoyloxychroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione
• 英文别名: [2-[[4-[(2,4-Dioxo-1,3-thiazolidin-5-yl)methyl]phenoxy]methyl]-2,5,7,8-tetramethyl-3,4-dihydrochromen-6-yl] pyridine-3-carboxylate
• CAS: 97323-02-9
• 化学式: C₃₀H₃₀N₂O₆S
• 分子量: 546.644
• InChiKey: NLYKYOJFKOSQBY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.8
• 重原子数：
  39
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  129
• 氢给体数：
  1
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  6-Hydroxy-2,5,7,8-tetramethyl-2-<(4-nitrophenoxy)methyl>chroman 在 palladium on activated charcoal 吡啶 、 copper(I) oxide 、 盐酸 、 氢气 、 溶剂黄146 、 sodium nitrite 作用下， 以 甲醇 、 苯 为溶剂， 120.0 ℃ 、380.0 kPa 条件下， 反应 17.83h， 生成 5-[4-(2,5,7,8-tetramethyl-6-nicotinoyloxychroman-2-ylmethoxy)benzyl]thiazolidine-2,4-dione
  参考文献：
  名称：

  Studies on hindered phenols and analogs. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation

  摘要：

  A series of hindered phenols were investigated as hypolipidemic and/or hypoglycemic agents with ability to inhibit lipid peroxidation. 1,3-Benzoxathioles (9 and 22), phenoxypentanoic acid (34), phenoxypentanol (35a), phenoxynonanol (35b), phenylchloropropionic acid having a chromanyl group (25), and a thiazolidine compound (27) derived from 25, all having a hindered phenol group, were prepared and examined. Compound 27 showed the expected biological properties in vivo and in vitro without any liver weight increase. Biological activities of the analogous thiazolidine compounds, 43-58, were compared. Thus, (+/-)-5-[4-[(6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)methoxy]- benzyl]-2,4-thiazolidinedione (27) (CS-045) was found to have all of our expected properties and was selected as a candidate for further development as a hypoglycemic and hypolipidemic agent.

  DOI：

  10.1021/jm00122a022

文献信息

• Thiazolidine derivatives, their preparation and compositions containing them
  申请人：SANKYO COMPANY LIMITED

  公开号：EP0139421B1

  公开（公告）日：1988-04-27
• YOSHIOKA, TAKAO;KITAZAWA, EIICI;KURUMADA, TOMOYUKI;YAMAZAKI, MITSUO;HASEG+
  作者：YOSHIOKA, TAKAO、KITAZAWA, EIICI、KURUMADA, TOMOYUKI、YAMAZAKI, MITSUO、HASEG+

  DOI：——

  日期：——
• MODULATION OF NEUROGENESIS BY PPAR AGENTS
  申请人：Barlow Carrolee

  公开号：US20100184806A1

  公开（公告）日：2010-07-22

  The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system including by stimulating or increasing neurogenesis, neuroproliferation, and/or neurodifferentiation. The disclosure includes compositions and methods based on use of a peroxisome proliferator-activated receptor (PPAR) agent, optionally in combination with one or more neurogenic agents, to stimulate or increase a neurogenic response and/or to treat a nervous system disease or disorder.
• US4572912A
  申请人：——

  公开号：US4572912A

  公开（公告）日：1986-02-25
• [EN] MODULATION OF NEUROGENESIS BY PPAR AGENTS<br/>[FR] MODULATION DE LA NEUROGENÈSE PAR DES AGENTS PPAR
  申请人：BRAINCELLS INC

  公开号：WO2011091033A1

  公开（公告）日：2011-07-28

  The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system including by stimulating or increasing neurogenesis, neuroproliferation, and/or neurodifferentiation. The disclosure includes compositions and methods based on use of a peroxisome proliferator-activated receptor (PPAR) agent, optionally in combination with one or more neurogenic agents, to stimulate or increase a neurogenic response and/or to treat a nervous system disease or disorder.